Zelluna Immunotherapy is at the forefront of developing innovative cell therapies aimed at treating solid tumors by harnessing the immune system's capabilities. The company focuses on creating "off-the-shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies, which combine the broad targeting potential of TCRs with the potent, allogeneic nature of NK cells. This dual mechanism is designed to address the challenges posed by tumor heterogeneity, allowing for precise targeting of cancer cells while maintaining the ability to recognize a wide range of tumor antigens. By integrating in-house TCR discovery and optimization, Zelluna aims to advance its lead product into clinical development, with a pipeline that includes multiple preclinical projects targeting well-validated antigens across various solid tumors.

The proprietary TCR-NK platform developed by Zelluna Immunotherapy is designed to enhance the effectiveness of cancer treatments by combining the strengths of TCRs and NK cells. TCRs are adept at recognizing specific antigens presented on the surface of abnormal cells, while NK cells possess a natural ability to identify and eliminate cancerous cells through various mechanisms, including the recognition of stress ligands and HLA loss. This innovative approach allows for a more comprehensive attack on tumors, potentially leading to deeper and more durable clinical responses. Zelluna's commitment to optimizing its TCR-NK therapies positions it as a promising player in the field of immuno-oncology, with the potential to significantly improve treatment outcomes for patients with solid cancers.

Norway

Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. 

For more info please visit www.zelluna.com


Cancer

Digestive System Diseases

Endocrine System Diseases

Lung Diseases

Urogenital Diseases

Zelluna Immunotherapy

Gastroesophageal cancer

Melanoma

Non-small cell lung carcinoma

Ovarian cancer

Synovial sarcoma

ZI-MA4-1

Biologics

Cell Therapies

Breast cancer

Cervical cancer

Gastric cancer

Lung cancer

Pancreatic cancer

ZI-KL1-1

Solid tumor/s

ZI-(PRAME)

Europe - West

Gene Therapy

Immuno-Oncology

Lentiviral Vector (LVV)

Therapeutic

Zelluna Immunotherapy

Company Details